Europe — EMA
Nuvaxovid Jn.1
Matrix M, the active ingredient in Nuvaxovid Jn.1, is a recombinant protein subunit presented as a vaccine for intramuscular use. It targets the SARS‑CoV‑2 Omicron Jn.1 variant and is intended for immunisation against…
Request sourcing
What is Matrix M, Sars-Cov-2, Variant Omicron Jn.1, Spike Protein, Recombinant, Expressed In Sf9 Cells Deriv?
Matrix M, the active ingredient in Nuvaxovid Jn.1, is a recombinant protein subunit presented as a vaccine for intramuscular use. It targets the SARS‑CoV‑2 Omicron Jn.1 variant and is intended for immunisation against COVID‑19 caused by this strain.
GNH USA supplies Nuvaxovid Jn.1 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.
What is Matrix M, Sars-Cov-2, Variant Omicron Jn.1, Spike Protein, Recombinant, Expressed In Sf9 Cells Deriv used for?
Nuvaxovid Jn.1 is a vaccine that addresses the SARS‑CoV‑2 Omicron Jn 1 variant pathway by inducing protective immunity against infection and severe disease of the variant in adults and the or the … … … etc…
Product details
Related products
Nuvaxovid Jn.1
Matrix M, Sars-Cov-2, Variant Omicron Jn.1, Spike Protein, Recombinant, Expressed In Sf9 Cells Deriv
Nuvaxovid Jn.1
Matrix M, Sars-Cov-2, Variant Omicron Jn.1, Spike Protein, Recombinant, Expressed In Sf9 Cells Deriv
Nuvaxovid Jn.1
Matrix M, Sars-Cov-2, Variant Omicron Jn.1, Spike Protein, Recombinant, Expressed In Sf9 Cells Deriv
Nuvaxovid Jn.1
Matrix M, Sars-Cov-2, Variant Omicron Jn.1, Spike Protein, Recombinant, Expressed In Sf9 Cells Deriv